User login
Key clinical point: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment strategy for patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). However, better patient selection and posttransplant strategies are needed to mitigate the risk of relapse.
Major finding: Pooled rates of overall survival, disease-free survival, complete remission, and molecular response in adult allo-HCT recipients were 84% (95% confidence interval [CI], 59%-99%), 66% (95% CI, 59%-73%), 56% (95% CI, 30%-80%), and 88% (95% CI, 62%-98%), respectively. Pooled rates of nonrelapse mortality and relapse were 20% (95% CI, 15%-26%) and 19% (95% CI, 10%-28%), respectively.
Study details: This was a systematic review and meta-analysis of 9 studies including 439 patients with TKI-resistant or intolerant CML-CP who received allo-HCT.
Disclosures: No funding source was identified. MA Moustafa reported consulting for Acrotech Biopharma and MA Kharfan-Dabaja reported consulting for Pharmacyclics and Daiichi Sankyo. Other authors declared no conflicts of interest.
Source: Yassine F et al. Hematol Oncol Stem Cell Ther. 2021 Mar 11. doi: 10.1016/j.hemonc.2021.02.003.
Key clinical point: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment strategy for patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). However, better patient selection and posttransplant strategies are needed to mitigate the risk of relapse.
Major finding: Pooled rates of overall survival, disease-free survival, complete remission, and molecular response in adult allo-HCT recipients were 84% (95% confidence interval [CI], 59%-99%), 66% (95% CI, 59%-73%), 56% (95% CI, 30%-80%), and 88% (95% CI, 62%-98%), respectively. Pooled rates of nonrelapse mortality and relapse were 20% (95% CI, 15%-26%) and 19% (95% CI, 10%-28%), respectively.
Study details: This was a systematic review and meta-analysis of 9 studies including 439 patients with TKI-resistant or intolerant CML-CP who received allo-HCT.
Disclosures: No funding source was identified. MA Moustafa reported consulting for Acrotech Biopharma and MA Kharfan-Dabaja reported consulting for Pharmacyclics and Daiichi Sankyo. Other authors declared no conflicts of interest.
Source: Yassine F et al. Hematol Oncol Stem Cell Ther. 2021 Mar 11. doi: 10.1016/j.hemonc.2021.02.003.
Key clinical point: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment strategy for patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). However, better patient selection and posttransplant strategies are needed to mitigate the risk of relapse.
Major finding: Pooled rates of overall survival, disease-free survival, complete remission, and molecular response in adult allo-HCT recipients were 84% (95% confidence interval [CI], 59%-99%), 66% (95% CI, 59%-73%), 56% (95% CI, 30%-80%), and 88% (95% CI, 62%-98%), respectively. Pooled rates of nonrelapse mortality and relapse were 20% (95% CI, 15%-26%) and 19% (95% CI, 10%-28%), respectively.
Study details: This was a systematic review and meta-analysis of 9 studies including 439 patients with TKI-resistant or intolerant CML-CP who received allo-HCT.
Disclosures: No funding source was identified. MA Moustafa reported consulting for Acrotech Biopharma and MA Kharfan-Dabaja reported consulting for Pharmacyclics and Daiichi Sankyo. Other authors declared no conflicts of interest.
Source: Yassine F et al. Hematol Oncol Stem Cell Ther. 2021 Mar 11. doi: 10.1016/j.hemonc.2021.02.003.